Literature DB >> 34993914

Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions.

Olena Mandrik1, Chloe Thomas2, Sophie Whyte2, James Chilcott2.   

Abstract

The calibration of cancer natural history models is often challenged by a lack of representative calibration targets, forcing modellers to rely on potentially incompatible datasets. Using a microsimulation colorectal cancer model as an example, the purposes of this paper are to (1) highlight the reasons for uncertainty in calibration targets, (2) illustrate practical and generalisable approaches for dealing with incompatibility in calibration targets, and (3) discuss the importance of future research in the area of incorporating uncertainty in calibration. The low quality of data and differences in populations, outcome definitions, and healthcare systems may result in incompatibility between the model and the data. Acknowledging reasons for data incompatibility allows assessment of the risk of incompatibility before calibrating the model. Only a few approaches are available to address data incompatibility, for instance addressing biases in calibration targets and their adjustment, relaxing the goodness-of-fit metric, and validation of the calibration targets to the data not used in the calibration. However, these approaches lack explicit comparison and validation, and so more research is needed to describe the nature and causes of indirect uncertainty (i.e. uncertainty that cannot be expressed in absolute quantitative forms) and identify methods for managing this uncertainty in healthcare modelling.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2022        PMID: 34993914     DOI: 10.1007/s40273-021-01125-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.558


  50 in total

1.  Calibrating models in economic evaluation: a seven-step approach.

Authors:  Tazio Vanni; Jonathan Karnon; Jason Madan; Richard G White; W John Edmunds; Anna M Foss; Rosa Legood
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

2.  Bayesian calibration of a natural history model with application to a population model for colorectal cancer.

Authors:  Sophie Whyte; Cathal Walsh; Jim Chilcott
Journal:  Med Decis Making       Date:  2010-12-02       Impact factor: 2.583

Review 3.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

Authors:  Michael Drummond; Marco Barbieri; John Cook; Henry A Glick; Joanna Lis; Farzana Malik; Shelby D Reed; Frans Rutten; Mark Sculpher; Johan Severens
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

5.  Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide.

Authors:  Joke Bilcke; Philippe Beutels; Marc Brisson; Mark Jit
Journal:  Med Decis Making       Date:  2011-06-08       Impact factor: 2.583

6.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

7.  Quantifying Uncertainty in Mechanistic Models of Infectious Disease.

Authors:  Lucy D'Agostino McGowan; Kyra H Grantz; Eleanor Murray
Journal:  Am J Epidemiol       Date:  2021-07-01       Impact factor: 4.897

8.  Nonidentifiability in Model Calibration and Implications for Medical Decision Making.

Authors:  Fernando Alarid-Escudero; Richard F MacLehose; Yadira Peralta; Karen M Kuntz; Eva A Enns
Journal:  Med Decis Making       Date:  2018-10       Impact factor: 2.583

9.  How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease.

Authors:  Isaac Corro Ramos; Martine Hoogendoorn; Maureen P M H Rutten-van Mölken
Journal:  Med Decis Making       Date:  2020-07-01       Impact factor: 2.583

10.  Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models.

Authors:  Koen Degeling; Maarten J IJzerman; Miriam Koopman; Hendrik Koffijberg
Journal:  BMC Med Res Methodol       Date:  2017-12-15       Impact factor: 4.615

View more
  2 in total

1.  Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.

Authors:  Olena Mandrik; James Chilcott; Chloe Thomas
Journal:  Prev Med       Date:  2022-05-06       Impact factor: 4.637

Review 2.  Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Thomas Otten; Rob Riemsma; Ben Wijnen; Nigel Armstrong; Lisa Stirk; Caroline Gordon; Bram Ramaekers; Jos Kleijnen; Manuela Joore; Sabine Grimm
Journal:  Pharmacoeconomics       Date:  2022-07-08       Impact factor: 4.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.